I-NEW YORK - I-Immunocore ithe ngoMvulo iya kuthengisa izabelo ze-3,733,333 kwi-private equity investment (PIPE) isivumelwano senkxaso-mali ekulindeleke ukuba ikhulise i-140 yezigidi zeedola.
Ngaphantsi kwesivumelwano, i-Immunocore iya kuthengisa isitokhwe sayo esiqhelekileyo kunye nesitokisi esingavoti esiqhelekileyo kwi-$ 37.50 ngesabelo ngasinye. Abatyalo-mali abakhoyo benkampani abathatha inxaxheba kwi-RTW Investments, i-Rock Springs Capital kunye ne-General Atlantic.Isivumelwano sePIPE kulindeleke ukuba siphele ngoJulayi 20.
Inkampani iya kusebenzisa imali ekhoyo ukuxhasa abaviwa bayo bemibhobho ye-oncology kunye ne-infectious disease, kubandakanywa nokuphuhliswa komgqatswa we-oncology okhokelayo, uKimmtrak (tebentafusp-tebn), ukunyanga i-HLA-A * 02: 01 isikhumba esilungileyo kunye ne-melanoma ye-uveal.Inkxaso-mali, kunye nengeniso evela kwi-Kimmtrak, kulindeleke ukuba ixhase imisebenzi ye-Immunocore2025.
Kulo nyaka, i-Kimmtrak ivunyiwe ukuba isetyenziswe kwizigulane ezine-HLA-A * 02: i-01 engabonakaliyo okanye i-metastatic uveal melanoma e-US, eYurophu nase-UK, phakathi kwamanye amazwe.
I-Immunocore iphinda iphuhlise abanye abaviwa abane be-oncology, kubandakanywa neziyobisi ezimbini ezongezelelweyo ze-T-cell receptor kwiSigaba se-I / II solingo kwii-tumor eziqinileyo eziphambili.Enye yamachiza iphuhliswa kwi-HLA-A * 02: i-01-positive kunye ne-MAGE-A4-positive izigulane, kunye nezinye iithagethi ze-HLA-A * 02: 01 kunye ne-PRAME-positive-positive ine-tumors ezimbini zokuphuhliswa kwenkampani.
Umgaqo-nkqubo waBucala.imigaqo neMiqathango.Copyright © 2022 GenomeWeb, icandelo leshishini le-Crain Communications.onke amalungelo agciniwe.